52 related articles for article (PubMed ID: 24843556)
1. Fingolimod ameliorates chronic experimental autoimmune neuritis by modulating inflammatory cytokines and Akt/mTOR/NF-κB signaling.
Feng Y; Feng F; Pan S; Zhang J; Li W
Brain Behav; 2023 Apr; 13(4):e2965. PubMed ID: 36917739
[TBL] [Abstract][Full Text] [Related]
2. Targeting Type 1 Diabetes: Selective Approaches for New Therapies.
Sheehy DF; Quinnell SP; Vegas AJ
Biochemistry; 2019 Jan; 58(4):214-233. PubMed ID: 30608114
[TBL] [Abstract][Full Text] [Related]
3. The role of sphingolipid signalling in diabetes‑associated pathologies (Review).
Ng ML; Wadham C; Sukocheva OA
Int J Mol Med; 2017 Feb; 39(2):243-252. PubMed ID: 28075451
[TBL] [Abstract][Full Text] [Related]
4. High Endothelial Venules and Lymphatic Vessels in Tertiary Lymphoid Organs: Characteristics, Functions, and Regulation.
Ruddle NH
Front Immunol; 2016; 7():491. PubMed ID: 27881983
[TBL] [Abstract][Full Text] [Related]
5. Combination treatment with fingolimod and a pathogenic antigen prevents relapse of glucose-6-phosphate isomerase peptide-induced arthritis.
Yoshida Y; Mikami N; Matsushima Y; Miyawaki M; Endo H; Banno R; Tsuji T; Fujita T; Kohno T
Immun Inflamm Dis; 2016 Sep; 4(3):263-73. PubMed ID: 27621810
[TBL] [Abstract][Full Text] [Related]
6. Insulin glargine: a new once-daily basal insulin for the management of type 1 and type 2 diabetes mellitus.
Lam S
Heart Dis; 2003; 5(3):231-40. PubMed ID: 12783637
[TBL] [Abstract][Full Text] [Related]
7. Insulin glargine: a systematic review of a long-acting insulin analogue.
Wang F; Carabino JM; Vergara CM
Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic approach for type 1 diabetes mellitus using the novel immunomodulator FTY720 (fingolimod) in combination with once-daily injection of insulin glargine in non-obese diabetic mice.
Tsuji T; Inoue M; Yoshida Y; Fujita T; Kaino Y; Kohno T
J Diabetes Investig; 2012 Mar; 3(2):132-7. PubMed ID: 24843556
[TBL] [Abstract][Full Text] [Related]
9. Oral therapy for type 1 diabetes mellitus using a novel immunomodulator, FTY720 (fingolimod), in combination with sitagliptin, a dipeptidyl peptidase-4 inhibitor, examined in non-obese diabetic mice.
Tsuji T; Yoshida Y; Fujita T; Kohno T
J Diabetes Investig; 2012 Oct; 3(5):441-8. PubMed ID: 24843604
[TBL] [Abstract][Full Text] [Related]
10. Long-term islet graft survival in streptozotocin- and autoimmune-induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720.
Fu F; Hu S; Deleo J; Li S; Hopf C; Hoover J; Wang S; Brinkmann V; Lake P; Shi VC
Transplantation; 2002 May; 73(9):1425-30. PubMed ID: 12023620
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulator FTY720 improves glucose homeostasis and diabetic complications by rejuvenation of β-cell function in nonhuman primate model of diabetes.
Wang YJ; Wang X; An A; Zang M; Xu L; Gong K; Song W; Li Q; Lu X; Xiao YF; Yu G; Ma ZA
Fundam Clin Pharmacol; 2022 Aug; 36(4):699-711. PubMed ID: 35064580
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic approach to steroid-resistant dermatitis using novel immunomodulator FTY720 (Fingolimod) in combination with betamethasone ointment in NC/Nga mice.
Tsuji T; Yoshida Y; Iwatsuki R; Inoue M; Fujita T; Kohno T
Biol Pharm Bull; 2012; 35(8):1314-9. PubMed ID: 22863931
[TBL] [Abstract][Full Text] [Related]
13. Prevention and cure of autoimmune diabetes in nonobese diabetic mice by continuous administration of FTY720.
Maki T; Gottschalk R; Ogawa N; Monaco AP
Transplantation; 2005 May; 79(9):1051-5. PubMed ID: 15880042
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
